Amylyx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
AMLX$30.91+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows provided by (used in) operating activities: | |||
| Net income (loss) | $49,271 | $(198,375) | $(87,931) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||
| Stock-based compensation expense | 37,161 | 21,714 | 3,136 |
| Depreciation expense | 1,088 | 487 | 52 |
| (Accretion) amortization of investment (discounts) premiums | (9,940) | (2,056) | 121 |
| Change in fair value of convertible notes | — | — | 5,228 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (24,744) | (15,306) | — |
| Inventories | (73,129) | (9,769) | — |
| Interest receivable | 23 | 487 | (144) |
| Prepaid expenses and other current assets | (4,817) | (5,221) | (4,486) |
| Operating lease right-of-use assets | 1,799 | 1,635 | — |
| Other assets | (231) | (456) | 125 |
| Accounts payable | 15,882 | 1,854 | 670 |
| Accrued expenses and deferred rent | 21,597 | 26,052 | 8,432 |
| Operating lease liabilities | (2,041) | (917) | — |
| Accrued interest and accrued interest—related parties | — | — | (2) |
| Net cash provided by (used in) operating activities | 11,919 | (179,871) | (74,799) |
| Cash flows provided by (used in) investing activities: | |||
| Purchases of property and equipment | (1,241) | (2,526) | (353) |
| Purchases of short-term investments | (300,826) | (415,873) | (49,053) |
| Proceeds from maturities of short-term investments | 394,120 | 179,411 | 3,000 |
| Net cash provided by (used in) investing activities | 92,053 | (238,988) | (46,406) |
| Cash flows provided by financing activities: | |||
| Repayment and proceeds from PPP loan | — | — | (263) |
| Proceeds from initial public offering | — | 200,897 | — |
| Proceeds from follow-on offering | — | 231,550 | — |
| Initial public offering costs paid | — | (2,044) | — |
| Follow-on offering costs paid | (136) | (803) | — |
| Proceeds from issuance of convertible notes—related parties | — | — | 14,272 |
| Proceeds from issuance of convertible notes, net of issuance costs | — | — | 11,887 |
| Issuance costs related to conversion of convertible notes | — | — | (50) |
| Proceeds from issuance of Series C-1 redeemable convertible preferred stock | — | — | 135,000 |
| Issuance costs related to issuance of Series C-1 redeemable convertible preferred stock | — | — | (209) |
| Proceeds from exercise of stock options | 6,994 | 2,189 | 343 |
| Withholding taxes paid on stock-based awards | (3,315) | — | — |
| Payment of deferred offering costs | — | — | (2,474) |
| Net cash provided by financing activities | 3,543 | 431,789 | 158,506 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | 160 | (65) | 13 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 107,675 | 12,865 | 37,314 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 63,245 | 50,380 | 13,066 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $170,920 | $63,245 | $50,380 |
| Supplemental disclosure of cash flow information: | |||
| Conversion of convertible notes and accrued interest into Series C-2 redeemable convertible preferred stock | $— | $— | $32,548 |
| Unrealized gain (loss) on short-term investments | $95 | $(26) | $(5) |
| Taxes withheld on stock-based awards included in accrued expenses | $23 | $— | $— |
| Purchases of property and equipment included in accounts payable | $20 | $98 | $22 |
| Deferred offering costs included in accounts payable and accrued expenses | $— | $— | $967 |
| Right-of-use assets and liabilities upon ASC 842 adoption | $— | $2,201 | $— |
| Right-of-use assets obtained in exchange for lease liabilities | $— | $4,958 | $— |
| Movement of deferred offering costs to equity | $— | $5,457 | $— |
| Follow-on offering costs included in accounts payable and accrued expenses | $— | $136 | $— |
| Conversion of preferred stock to common stock upon initial public offering | $— | $239,351 | $— |
| Income taxes paid | $6,389 | $27 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.